Sangamo BioSciences will provide Genentech with access to its zinc finger DNA-binding protein (ZFP) technology and will design and engineer ZFP nucleases (ZFN™).
“Our technology has the potential to change the speed and efficiency of cell engineering to meet the increased demand for proteins in a variety of industries, including pharmaceutical protein manufacturing,” adds Lamphier.
Genentech will use Sangamo’s platform to evaluate and generate cell lines with characteristics for protein pharmaceutical production purposes.
“We have engineered ZFNs to facilitate the efficient generation of production cell lines with altered traits,” says Edward Lanphier, Sangamo’s president and CEO.
Though there are many kinds of transcription factors, only ZFPs are amenable to engineering and precise targeting of a particular gene or genes of interest, according to Sangamo. ZFNs are engineered forms of ZFPs that also contain a nuclease component, which can induce modification of a target gene of interest.